[go: up one dir, main page]

AR027748A1 - Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma - Google Patents

Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma

Info

Publication number
AR027748A1
AR027748A1 ARP010101516A ARP010101516A AR027748A1 AR 027748 A1 AR027748 A1 AR 027748A1 AR P010101516 A ARP010101516 A AR P010101516A AR P010101516 A ARP010101516 A AR P010101516A AR 027748 A1 AR027748 A1 AR 027748A1
Authority
AR
Argentina
Prior art keywords
globules
small spheres
stavudine
spheres
extrusion
Prior art date
Application number
ARP010101516A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR027748A1 publication Critical patent/AR027748A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se proporcionan formas de dosificacion prolongada de estavudina que comprenden pequenas esferas o globulos formados por extrusion-formacion de pequenasesferas o globulos y recubiertos con un recubrimiento de sellado. Las pequenas esferas o globulos s e recubren también con un recubrimiento de liberacionmodificada de modo que una cápsula de gelatina rígida que contiene tales pequenas esferas o globulos proporcionará niveles en sangra de estavudina duranteaproximadamente 24 horas. Las pequenas esfe ras o globulos se preparan de una mezcla seca de estavudina, un agente formador de pequenas esferas o globulos, undiluyente adecuado y una cantidad estabilizadora de estearato de magnesio. El estearato de magnesio, en contraste con otros aditivos far macéuticos similares,se encontro que estabiliza a la estavudina contra la degradacion debido a hidrolisis en presencia de la cantidad limitada de agua necesaria para el proceso deextrusion-formacion de pequenas esferas o globulos. También se incluye en el alcance de la presente cápsulas de gelatina rígida que contienen, además de laspequenas esferas o globulos de estavudina, pequenas esferas o globulos similares que contienen otros agentes terapéuticos utilizados para tratar infeccionesretrovira les.
ARP010101516A 2000-03-30 2001-03-29 Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma AR027748A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19358800P 2000-03-30 2000-03-30

Publications (1)

Publication Number Publication Date
AR027748A1 true AR027748A1 (es) 2003-04-09

Family

ID=22714247

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101516A AR027748A1 (es) 2000-03-30 2001-03-29 Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma

Country Status (26)

Country Link
US (1) US7135465B2 (es)
EP (1) EP1267879A2 (es)
JP (1) JP2003528905A (es)
KR (1) KR20030011805A (es)
CN (1) CN1187052C (es)
AR (1) AR027748A1 (es)
AU (1) AU2001249591A1 (es)
BG (1) BG107157A (es)
BR (1) BR0109602A (es)
CA (1) CA2404687A1 (es)
CZ (1) CZ20023003A3 (es)
EE (1) EE200200564A (es)
GE (1) GEP20043285B (es)
HU (1) HUP0302631A2 (es)
IL (1) IL151475A0 (es)
LT (1) LT5045B (es)
LV (1) LV12939B (es)
MX (1) MXPA02009534A (es)
NO (1) NO20024645L (es)
NZ (1) NZ522250A (es)
PE (1) PE20011179A1 (es)
PL (1) PL366089A1 (es)
RU (1) RU2239435C2 (es)
SK (1) SK12822002A3 (es)
WO (1) WO2001074329A2 (es)
ZA (1) ZA200207760B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
MXPA05000018A (es) * 2002-06-27 2005-04-08 Cilag Ag Formulaciones de pellas esfericas.
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100548309C (zh) * 2004-11-24 2009-10-14 东北制药总厂 司他夫定缓释片剂
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
JP2008543845A (ja) * 2005-06-16 2008-12-04 フォーレスト ラボラトリーズ， インコーポレイテッド 放出調節および即放性メマンチンビーズ製剤
KR20080053317A (ko) * 2005-08-31 2008-06-12 씨아이피엘에이 엘티디. 라미부딘, 스타부딘 및 네비라핀을 포함하는 약학적 조합물
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
ME01617B (me) 2006-01-20 2014-09-20 Janssen R&D Ireland Dugotrajno tretiranje hiv-infekcije s tcm278
WO2007112581A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
JP5349290B2 (ja) * 2006-04-03 2013-11-20 オディディ，イサ 薬物送達組成物およびそれを含む医薬品、ならびにその製造方法
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
CN102319181B (zh) * 2011-09-08 2014-07-16 广东大华农动物保健品股份有限公司 一种微囊型动物药品的包被工艺
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
WO2016010741A1 (en) * 2014-07-17 2016-01-21 Dow Global Technologies Llc Ethylcellulose dispersion and film
CN105511174A (zh) * 2016-01-05 2016-04-20 深圳市华星光电技术有限公司 液晶显示面板和显示装置

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671963A (en) * 1983-10-28 1987-06-09 Germino Felix J Stearate treated food products
US4670270A (en) * 1984-05-07 1987-06-02 Germino Felix J Stearate treated food products
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US4978655A (en) * 1986-12-17 1990-12-18 Yale University Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
BR9206996A (pt) 1991-12-30 1995-12-05 Fmc Corp Composição adequada para preparar esferóides por esferoidização processo para produzir um material em partículas processo para produzir uma forma de dosagem de sólido esferoidizado em partículas e forma de dosagem sólida
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
US5869097A (en) * 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
GB9403449D0 (en) 1994-02-23 1994-04-13 Wellcome Found Therapeutic benzonitriles
CA2183653A1 (en) 1994-03-07 1995-09-14 Roger Dennis Tung Sulphonamide derivatives as aspartyl protease inhibitors
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
KR19980701739A (ko) 1995-02-23 1998-06-25 디르크 반테 신경보호제로서 융합된 벤조티아졸의 용도
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
EA001957B1 (ru) 1995-12-15 2001-10-22 Вироден Фармасьютикал Холдингс (Проприетэри) Лимитед КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ СПИДа
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US5883252A (en) 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US5905068A (en) 1996-09-24 1999-05-18 Abbott Laboratories Retroviral protease inhibiting compounds
JP4863534B2 (ja) 1996-10-25 2012-01-25 スパーナス ファーマシューティカルズ インコーポレイテッド 可溶形態浸透用量送達システム
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6136827A (en) 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
WO1999007342A1 (en) 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6692767B2 (en) * 1997-09-19 2004-02-17 Shire Laboratories Inc. Solid solution beadlet
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6013644A (en) 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
BR9813691A (pt) 1997-12-19 2000-10-10 Takeda Chemical Industries Ltd Composição farmacêutica para antagonizar o ccr5, uso do composto ou um sal deste em combinação com um inibidor de protease e/ou um inibidor da transcriptase reversa, e, processo para antagonizar o ccr5.
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
MXPA00012842A (es) 1998-06-24 2004-06-22 Univ Emory Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
AU763431B2 (en) 1999-03-31 2003-07-24 Uaf Technologies And Research Llc Viral treatment
US6136835A (en) 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections

Also Published As

Publication number Publication date
RU2239435C2 (ru) 2004-11-10
RU2002126540A (ru) 2004-03-27
KR20030011805A (ko) 2003-02-11
LT2002099A (en) 2003-04-25
NO20024645D0 (no) 2002-09-27
LT5045B (lt) 2003-08-25
JP2003528905A (ja) 2003-09-30
BR0109602A (pt) 2004-06-29
CA2404687A1 (en) 2001-10-11
PL366089A1 (en) 2005-01-24
NO20024645L (no) 2002-09-27
EP1267879A2 (en) 2003-01-02
PE20011179A1 (es) 2001-12-06
HUP0302631A2 (hu) 2003-11-28
US20020002147A1 (en) 2002-01-03
CN1420774A (zh) 2003-05-28
US7135465B2 (en) 2006-11-14
SK12822002A3 (sk) 2003-02-04
CZ20023003A3 (cs) 2002-11-13
EE200200564A (et) 2004-06-15
AU2001249591A1 (en) 2001-10-15
NZ522250A (en) 2004-09-24
LV12939B (en) 2003-04-20
WO2001074329A2 (en) 2001-10-11
ZA200207760B (en) 2004-01-30
CN1187052C (zh) 2005-02-02
MXPA02009534A (es) 2003-05-14
BG107157A (en) 2003-06-30
WO2001074329A3 (en) 2002-05-10
IL151475A0 (en) 2003-04-10
GEP20043285B (en) 2004-07-26

Similar Documents

Publication Publication Date Title
AR027748A1 (es) Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma
NO971965L (no) Farmasöytisk preparat inneholdende en smeltbar bærer og fremgangsmåte for fremstilling derav
ES2159591T3 (es) Composicion de liberacion controlada.
CA2323102A1 (en) Monolithic tablet for controlled drug release
BRPI0412059A (pt) método para a preparação de formulação de liberação controlada
ES2185758T3 (es) Utilizacion de esteres grasos etoxilados como compuestos auto-emulsionables.
BR0109575A (pt) Formulação terapêutica, forma de dosagem oral, processo para a preparação de pelo menos uma pequena conta, e, pequena conta
BR9906372A (pt) Composição farmaceutica aquosa para aplicação na mucosa
CO5150202A1 (es) Composicion de tisu facial y metodo para usarla para el secuestro de irritantes de la piel de la secrecion nasal
ES2107235T3 (es) Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.
BR0116945A (pt) Uma preparação para prevenção de restenose
ATE227136T1 (de) Mittel zur verstaerkten aufnahme polarer arzneistoffe aus dem kolon
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
ES8305582A1 (es) Metodo para producir una composicion medicinal que comprende un gel acuoso reabsorbible de proteina fibrosa y agente an-tibacteriano de transferencia de metilol.
CO5570656A2 (es) Liberacin controlada de una sustancia activa a un entorno rico en grasa
PE71699A1 (es) Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
ES2157964T3 (es) Procedimiento de estabilizacion de vesiculas de lipido(s) anfifilo(s) y composicion para aplicacion topica que contiene dichas vesiculas estabilizadas.
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
AR019622A1 (es) Composicion dentifrica que contiene ingredientes reactivos encapsulados y un metodo para aplicar ajustes terapeuticos a los dientes utilizando dichacomposicion
GB1484972A (en) Method of sterilising medical and surgical instruments
PE84399A1 (es) Formas de dosificacion de sertralina de liberacion retardada
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
KR970703774A (ko) 활성물질 방출이 지연된 카바마제핀 약제(Carbamazepine medicament with retarded active substance release)
KR920014474A (ko) 담석 붕괴용 제제
BRPI0510694A (pt) composições farmacêuticas compreendendo ingredientes ativos concentrados encapsuladas em gelatina mole

Legal Events

Date Code Title Description
FB Suspension of granting procedure